{"id":329,"date":"2025-07-02T04:35:00","date_gmt":"2025-07-02T04:35:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=329"},"modified":"2026-05-07T23:23:14","modified_gmt":"2026-05-07T23:23:14","slug":"retatrutide-vs-tirzepatide-best-glp-1-antagonist","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/","title":{"rendered":"Retatrutide vs Tirzepatide: Best GLP-1 Antagonist?"},"content":{"rendered":"<p>Curious about the key differences between retatrutide and tirzepatide when it comes to weight loss and metabolic health? In this article, we\u2019ll break down how these two peptides work, their effectiveness, and what the future might hold for them.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav>\n<ul class='ez-toc-list ez-toc-list-level-1 ' >\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Retatrutide_Compared_to_Tirzepatide\" >Retatrutide Compared to Tirzepatide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#A_Closer_Look_at_Retatrutide_and_Tirzepatide\" >A Closer Look at Retatrutide and Tirzepatide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#What_You_Should_Know_About_Retatrutide\" >What You Should Know About Retatrutide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#What_You_Should_Know_About_Tirzepatide\" >What You Should Know About Tirzepatide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#How_These_Peptides_Work\" >How These Peptides Work<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#How_Retatrutide_Works\" >How Retatrutide Works<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#How_Tirzepatide_Works\" >How Tirzepatide Works<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Comparing_Weight_Loss_Effects\" >Comparing Weight Loss Effects<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Weight_Loss_Results_With_Retatrutide\" >Weight Loss Results With Retatrutide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Weight_Loss_Results_With_Tirzepatide\" >Weight Loss Results With Tirzepatide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Why_This_Matters_for_Type_2_Diabetes\" >Why This Matters for Type 2 Diabetes<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Maintaining_Weight_Loss\" >Maintaining Weight Loss<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Whats_Next\" >What\u2019s Next?<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#What_to_Expect_With_Retatrutide\" >What to Expect With Retatrutide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#What_to_Expect_With_Tirzepatide\" >What to Expect With Tirzepatide<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Final_Thoughts\" >Final Thoughts<\/a><\/li>\n<li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/lotilabs.com\/resources\/retatrutide-vs-tirzepatide-best-glp-1-antagonist\/#Frequently_Asked_Questions\" >Frequently Asked Questions<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Retatrutide_Compared_to_Tirzepatide\"><\/span><span class=\"ez-toc-section\" id=\"Retatrutide_Compared_to_Tirzepatide\"><\/span>Retatrutide Compared to Tirzepatide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide and Tirzepatide are both promising new peptides under investigation that seem to outperform existing treatments by targeting different hormonal pathways to improve metabolic control.<\/p>\n<p>Retatrutide is a newer triple-agonist that activates GLP-1, GIP, and glucagon receptors. Early studies show it can help people lose over 20% of their body weight under controlled conditions. Tirzepatide, on the other hand, is a dual agonist targeting GLP-1 and GIP receptors, with proven benefits for metabolic health.<\/p>\n<p>Research so far suggests Retatrutide can lead to about 24.2% weight loss over 48 weeks, potentially outperforming other peptides. Tirzepatide has shown around 15% weight loss in people with blood sugar issues.<\/p>\n<p>Both peptides are still being studied for safety and long-term effects. Retatrutide might be available for research use by 2025, while Tirzepatide continues to be explored for broader metabolic benefits.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"A_Closer_Look_at_Retatrutide_and_Tirzepatide\"><\/span><span class=\"ez-toc-section\" id=\"A_Closer_Look_at_Retatrutide_and_Tirzepatide\"><\/span>A Closer Look at Retatrutide and Tirzepatide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Both retatrutide and tirzepatide are often mentioned as leading compounds in the fight against obesity and metabolic disorders. Retatrutide, as a new triple-agonist, works through multiple hormonal pathways, showing promise for treating obesity and metabolic syndrome. Tirzepatide, a dual agonist, has already demonstrated effectiveness in weight loss, blood sugar control, and receptor activity in real-world use.<\/p>\n<p>These peptides are being investigated for obesity treatment, which often comes with conditions like high blood pressure and high cholesterol.<\/p>\n<p>Retatrutide seems to offer extra benefits thanks to its triple receptor action, leading to significant weight loss and improved metabolism. Semaglutide and Tirzepatide, which target GLP-1 and GIP receptors, also show promising results. Retatrutide\u2019s added effect on glucagon receptors may give it an edge.<\/p>\n<p>Both peptides have gone through early clinical trials but are mostly still in research phases. Ongoing studies aim to expand their use based on encouraging results reported in top medical journals. Retatrutide is being tested for obesity and type 2 diabetes under strict regulatory oversight. There\u2019s also interest in its effects on insulin regulation and chronic kidney disease.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_You_Should_Know_About_Retatrutide\"><\/span><span class=\"ez-toc-section\" id=\"What_You_Should_Know_About_Retatrutide\"><\/span>What You Should Know About Retatrutide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide is a triple-agonist that targets GLP-1, GIP, and glucagon receptors. Its action on the glucagon receptor plays a key role in controlling metabolism. By hitting multiple hormonal targets, Retatrutide can promote weight loss and better blood sugar control. Studies suggest it\u2019s more effective than single or dual agonists because of this triple action.<\/p>\n<p>Research shows Retatrutide can lead to impressive weight loss, with some animal studies reporting over 20% reduction in body weight. It also helps improve insulin sensitivity and reduce appetite, making it a strong candidate for treating obesity and metabolic issues.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_You_Should_Know_About_Tirzepatide\"><\/span><span class=\"ez-toc-section\" id=\"What_You_Should_Know_About_Tirzepatide\"><\/span>What You Should Know About Tirzepatide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tirzepatide works by activating two receptors: GLP-1 and GIP. GIP, or glucose-dependent insulinotropic polypeptide, helps control blood sugar and supports weight loss, making Tirzepatide a promising treatment for type 2 diabetes. It also helps reduce insulin resistance, adding to its benefits.<\/p>\n<p>After approval, Tirzepatide showed weight loss in animal studies and has since been effective in improving metabolic health and controlling weight by targeting these two receptors.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_These_Peptides_Work\"><\/span><span class=\"ez-toc-section\" id=\"How_These_Peptides_Work\"><\/span>How These Peptides Work<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide and Tirzepatide are new peptides for weight loss and diabetes, but they work a bit differently. Retatrutide activates three receptors\u2014GIP, GLP-1, and glucagon\u2014at the same time. This helps regulate blood sugar, curb appetite, and boost metabolism. The glucagon receptor activation might also help with weight control and improving kidney function in diabetes.<\/p>\n<p>Tirzepatide targets just two receptors, GIP and GLP-1, stimulating insulin release when blood sugar is high and making you feel fuller to eat less. Both peptides have been shown to cause significant weight loss and better blood sugar control, with Retatrutide showing stronger effects in some experimental models, especially those related to diabetic kidney disease.<\/p>\n<p>Understanding how these peptides work helps explain their effects. Retatrutide\u2019s triple action on GLP-1, GIP, and glucagon receptors supports weight loss and metabolic health. Both peptides also influence gut bacteria and cellular metabolism, which affects inflammation, insulin response, and kidney disease progression. In animal studies, these peptides are often given via intraperitoneal injections, and researchers measure markers like serum butyrate to track metabolic and kidney health.<\/p>\n<p>Tirzepatide\u2019s dual action improves blood sugar control and helps with weight loss, also improving important serum markers related to metabolism and kidney function.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Retatrutide_Works\"><\/span><span class=\"ez-toc-section\" id=\"How_Retatrutide_Works\"><\/span>How Retatrutide Works<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide\u2019s triple-agonist effect on GLP-1, GIP, and glucagon receptors makes it more effective than peptides that target only one or two pathways. This leads to steady weight loss and better metabolism over time.<\/p>\n<p>Besides metabolic benefits, Retatrutide also reduces fibrosis and inflammation in diabetic kidney disease models, lowering collagen I expression and helping restore kidney function.<\/p>\n<p>Its ability to cause significant weight loss makes Retatrutide a promising option for future weight and metabolic health treatments.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"How_Tirzepatide_Works\"><\/span><span class=\"ez-toc-section\" id=\"How_Tirzepatide_Works\"><\/span>How Tirzepatide Works<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tirzepatide\u2019s dual action on GLP-1 and GIP receptors helps regulate appetite and body weight effectively. Clinical studies back its role in blood sugar control and significant weight loss. Tirzepatide also lowers bad cholesterol like LDL and total cholesterol, improving metabolic health.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Comparing_Weight_Loss_Effects\"><\/span><span class=\"ez-toc-section\" id=\"Comparing_Weight_Loss_Effects\"><\/span>Comparing Weight Loss Effects<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Lab studies show Retatrutide can cause weight loss that sometimes surpasses Tirzepatide. Both peptides reduce appetite, helping patients eat less and lose weight faster than other medications.<\/p>\n<p>Early research suggests both peptides may have advantages over existing weight loss peptides, but more studies are needed.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weight_Loss_Results_With_Retatrutide\"><\/span><span class=\"ez-toc-section\" id=\"Weight_Loss_Results_With_Retatrutide\"><\/span>Weight Loss Results With Retatrutide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Initial research predicts Retatrutide can lead to successful weight loss in controlled settings, mainly by suppressing appetite. Some data show body weight reductions of over 30% in certain cases, highlighting its strong potential.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Weight_Loss_Results_With_Tirzepatide\"><\/span><span class=\"ez-toc-section\" id=\"Weight_Loss_Results_With_Tirzepatide\"><\/span>Weight Loss Results With Tirzepatide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tirzepatide has demonstrated significant weight loss in trials, with about 15% body weight reduction reported.<\/p>\n<p>Research supports Tirzepatide\u2019s use for obesity and metabolic improvements.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Why_This_Matters_for_Type_2_Diabetes\"><\/span><span class=\"ez-toc-section\" id=\"Why_This_Matters_for_Type_2_Diabetes\"><\/span>Why This Matters for Type 2 Diabetes<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Type 2 diabetes is a complex disease involving blood sugar control, heart problems, nerve issues, and kidney damage. Protecting kidney function is a key goal of treatment.<\/p>\n<p>GLP-1 receptor agonists help normalize blood sugar and promote weight loss, offering benefits for both diabetes and obesity. They also protect kidneys and slow chronic kidney disease.<\/p>\n<p>Retatrutide, which acts on GLP-1, GIP, and glucagon receptors, is being studied for weight loss and improving metabolic markers. It may also slow diabetic kidney disease and protect kidney function in animal models.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Maintaining_Weight_Loss\"><\/span><span class=\"ez-toc-section\" id=\"Maintaining_Weight_Loss\"><\/span>Maintaining Weight Loss<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Keeping weight off is just as important as losing it. Studies on diabetic kidney disease in animals show metabolic and kidney health can be improved with these peptides.<\/p>\n<p>GLP-1 receptor agonists have proven effective for weight loss and metabolic improvements, supporting long-term weight management.<\/p>\n<p>Retatrutide\u2019s triple-agonist effect leads to widespread weight loss and better physical performance in studies.<\/p>\n<p>Research continues to find the best ways to maintain weight loss while supporting metabolism and body function.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Whats_Next\"><\/span><span class=\"ez-toc-section\" id=\"Whats_Next\"><\/span>What\u2019s Next?<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide and Tirzepatide are set to play big roles in future weight loss and metabolic health treatments. Ongoing studies will clarify their benefits and safety.<\/p>\n<p>Results from Retatrutide\u2019s phase 3 trials, expected by 2025, will help compare its effectiveness. Long-term safety and efficacy studies for Tirzepatide are also progressing.<\/p>\n<p>Combining data from multiple studies will be important to fully understand these peptides. Future research will tackle remaining questions about safety, how they work, and long-term outcomes.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_to_Expect_With_Retatrutide\"><\/span><span class=\"ez-toc-section\" id=\"What_to_Expect_With_Retatrutide\"><\/span>What to Expect With Retatrutide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Researchers are testing different doses of Retatrutide, including lower doses to reduce side effects.<\/p>\n<p>There\u2019s hope Retatrutide will soon be available as a powerful option for weight and metabolic health.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_to_Expect_With_Tirzepatide\"><\/span><span class=\"ez-toc-section\" id=\"What_to_Expect_With_Tirzepatide\"><\/span>What to Expect With Tirzepatide<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Tirzepatide has a positive outlook, with ongoing studies confirming its safety and lasting effectiveness. Early data show it helps with weight loss and blood sugar control in type 2 diabetes.<\/p>\n<p>More research will expand its uses and confirm safety.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Final_Thoughts\"><\/span><span class=\"ez-toc-section\" id=\"Final_Thoughts\"><\/span>Final Thoughts<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Retatrutide and Tirzepatide are exciting new options for weight and metabolic health. Retatrutide\u2019s triple-agonist approach appears more effective than Tirzepatide\u2019s dual action in early studies.<\/p>\n<p>Research is ongoing to better understand how these peptides work, their safety, and how well they help manage metabolic diseases.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span>Frequently Asked Questions<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>What is Retatrutide used for?<\/strong><br \/>Retatrutide is being studied for weight loss and improving metabolic markers by targeting multiple hormones.<\/p>\n<p><strong>How does Tirzepatide work?<\/strong><br \/>Tirzepatide activates GLP-1 and GIP receptors to help control blood sugar and promote weight loss.<\/p>\n<p><strong>What studies have been done on Retatrutide?<\/strong><br \/>Some studies report mild side effects at high doses. Research by Bakris et al. looked at its kidney-protective effects.<\/p>\n<p><strong>How does Retatrutide compare to other weight loss peptides?<\/strong><br \/>Early reports suggest it may be more effective than similar medications.<\/p>\n<p><strong>What\u2019s next for Tirzepatide research?<\/strong><br \/>Focus is on long-term safety, effectiveness, and expanding its uses.<\/p>\n<hr class=\"wp-block-separator\" \/>\n<p><em>References:<\/em><\/p>\n<ul class=\"wp-block-list\">\n<li>Naeem M, Imran L, Banatwala UESS. Unleashing the power of retatrutide: a possible triumph over obesity and overweight: a correspondence. Health Sci Rep. 2024;7:e1864.<\/li>\n<li>Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3437943, a novel triple receptor agonist, in type 2 diabetes: a randomized, placebo-controlled, phase 1 trial. Lancet. 2022;399(10329):1413-1424.<\/li>\n<li>Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.<\/li>\n<li>United States Food and Drug Administration. The FDA&#8217;s concerns about unapproved GLP-1 peptides for weight loss. 2023.<\/li>\n<li>Eli Lilly and Company. Retatrutide (LY3437943), phase 2 data. 2023.<\/li>\n<li>Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.<\/li>\n<li>Care Pharmacy. Applications, uses, availability, and supplemental characteristics of retatrutide. 2024.<\/li>\n<li>Gard Wellness Solutions. Retatrutide: An In-depth Acquisitions Guide. 2024.<\/li>\n<\/ul>\n<hr \/>\n<h3>Research-Grade GLP Receptor Agonist Compounds at Loti Labs<\/h3>\n<p>Loti Labs supplies retatrutide formulations for preclinical and in vitro GLP receptor research. Available concentrations include <a href=\"https:\/\/lotilabs.com\/product\/retatrutide-5mg\/\">Reta 5mg<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/retatrutide-10mg\/\">Reta 10mg<\/a>, <a href=\"https:\/\/lotilabs.com\/product\/retatrutide-20mg\/\">Reta 20mg<\/a>, and <a href=\"https:\/\/lotilabs.com\/product\/retatrutide-30mg\/\">Reta 30mg<\/a>. All batches include third-party HPLC Certificate of Analysis. Supplied for research use only.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Curious about the key differences between retatrutide and tirzepatide when it comes to weight loss and metabolic health? In this article, we\u2019ll break down how these two peptides work, their effectiveness, and what the future might hold for them. Table of Contents Toggle Retatrutide Compared to Tirzepatide A Closer Look at Retatrutide and Tirzepatide What [&#8230;]\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-329","post","type-post","status-publish","format-standard","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/329","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=329"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/329\/revisions"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=329"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=329"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=329"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}